Metastatic spinal cord compression: Incidence, epidemiology and prognostic factors

Epidemiology of spinal metastases, metastatic epidural spinal cord compression and pathologic vertebral compression fractures in patients with solid tumors: A systematic review

“…In patients with a solid tumor, the cumulative incidence ranges from 0.29 to 10.00% (mean 2.84%, 95% CI: 1.54%-4.14%) [15] , [16] , [22] , [24] , [42] , [43] . Zaikova et al report an annual incidence of 8.1 per 100.000 inhabitants [22] .…”

“…For patients with MESCC, an overall median survival of 2.9-3.1 months [42] , [43] , [52] is reported, with longer median survival times for breast (5.0 months) and prostate (4.0 months) carcinoma [43] as compared to lung carcinoma (1.5-2.8 months 33,43). MESCC is associated with an increased risk of death (Hazard ratio 1.62 (95% CI: 1.18-2.23)) [49] .…”

Comparison of the postoperative pain change and spinal stenosis rate between percutaneous vertebroplasty combined with radiofrequency ablation and with 125I particle implantation in the treatment of metastatic spinal cord compression: A retrospective study

“…In addition, the reported median survival time of patients with MSCC is 3–6 months. 3 Without treatment, the life expectancy of a patient with MSCC is approximately 1 month. 22 The primary tumor histology affected not only the time between diagnosis and MSCC, but also the postoperative survival time of patients.…”

“… 1 The incidence of MSCC is approximately 2%–10%, with most cases occurring in the thoracolumbar region. 2 , 3 In MSCC, the most common primary tumors are prostate, breast, and lung cancers. The clinical manifestations of MSCC are local pain in the back and weakness and hypoesthesia of the limbs (≥75% of cases), and the prognosis is often poor.…”

Predictors of overall survival in non‐small‐cell lung cancer patients with metastatic spinal cord compression treated with short‐course radiotherapy

“…Metastatic spinal cord compression is considered a complication of high importance in the morbidity of cancer patients and may cause pain, paralysis of body structures below the level of metastasis, and urinary and faecal incontinence, negatively affecting their quality of life and prognosis (Campillo‐Recio et al, 2019; Duran et al, 2017; Morgen et al, 2016). Treatment of this complication includes the use of analgesics, corticosteroids, chemotherapy, radiotherapy and surgery, these modalities being administered alone or in combination with other therapies.…”